Purchase Order 75N95022P00407
Award Date 8/5/22
Potential Completion Date 8/4/25
Potential Value $86K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Wilmington, NC 28405, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm fixed-price purchase order awarded by the National Institute on Drug Abuse (NIDA), on behalf of the National Institute of Neurological Disorders and Stroke (NINDS), to Curia Global Inc. (doing business as Amri) for the non-GMP synthesis of up to 100 compounds in 2-10 milligram quantities. The purpose is to identify molecules that bind the KIAA0203 protein, which could potentially lead to the development of a new Alzheimer's drug. The contract has a period of performance from...
- <p>The National Institute on Drug Abuse (NIDA), a civilian federal agency, awarded a $24,900 firm fixed price purchase order contract to Pelago Bioscience AB, a for-profit limited liability company. The contract is for the development of a new assay to test compounds of interest. The period of performance runs from the award date of September 9, 2024 through September 8, 2025. This contract award does not have a set-aside designation.</p>
- <p>This is a $493,000.00 firm fixed price delivery order contract awarded by the National Institute on Drug Abuse (NIDA), a civilian federal agency, to Catalent Maryland, Inc. (doing business as Paragon Biosciences). The contract does not have a set-aside designation. The contract supports work related to NIDA's programs, with an ultimate completion date of September 27, 2017. Catalent Maryland, Inc. is the prime contractor for this award.</p>
- This is a $90,000.00 firm fixed price purchase order awarded by the National Institute on Drug Abuse (NIDA), which is a civilian agency of the U.S. government. The contract, which does not have a set-aside designation, is for the "SMALL MOLECULES FOR NCATS PHARMACOLOGICALLY ACTIVE CHEMICAL TOOLBOX (NPACT)" program and was awarded to DC Chemicals LIMITED, a for-profit limited liability company, on July 9, 2015. The period of performance for this contract ends on November 30, 2015.
- The National Institute on Drug Abuse awarded a firm fixed-price purchase order to Rashid Adnan (UEI: LMD7VXK1MQV9) on March 6, 2020, with a ceiling value of $26,900. The contract, which was solicited without a set-aside designation, calls for the awardee to study the pathophysiology and develop related research deliverables, with work to be performed in Greenbelt, Maryland. The solicitation was posted on January 31, 2020, with a bid due date of February 14, 2020, and the contract ultimately...
- The National Institute on Drug Abuse (NIDA), a civilian federal agency, awarded a definitive contract to Lowery Creek Consulting, LLC on February 24, 2017, with an ultimate completion date of May 22, 2022. The contract, valued at $85,758.00 on a firm fixed-price basis, was executed without a set-aside designation. The work was performed at the NIDA facility in Bethesda, Maryland, and involved CMC Consulting Services under the NINDS BPN/Lowery Creek program. The primary purpose of this contract...
- This is a firm fixed-price purchase order awarded to Paul C. Anderson, a medicinal chemistry consultant, to de-obligate unexpended and expiring Fiscal Year 2020 funding for the National Institute on Drug Abuse (NIDA), a civilian agency. The contract has a ceiling value of $342,435.00 and a completion date of February 27, 2023. It was awarded on February 28, 2018 and does not have a set-aside designation. This contract supports NIDA's administrative efforts to close out older fiscal year funds in...
- The U.S. National Institute on Drug Abuse (NIDA) has awarded a $139,267.77 firm fixed-price purchase order to CTR Consulting LLC, a for-profit limited liability company based in the UK, for technical consulting services and data analysis of Glucagon-like Peptide-1 (GLP-1) analogues. The contract is part of NIDA's research efforts to investigate the potential use of GLP-1 analogues as a treatment for alcohol use disorder. The period of performance is from September 11, 2023 to September 10, 2024,...
- The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a $10,465 firm fixed price purchase order to Cambrex High Point, Inc. to support retesting of the GLWL-01 reference standard and project specific funding. Cambrex will perform the work in Baltimore, Maryland over a one year period from July 2023 through July 2024. The National Institute on Drug Abuse conducts important biomedical research on drug abuse and addiction to improve...
- This is a $100,000.00 firm-fixed-price purchase order awarded by the National Institute on Drug Abuse (NIDA), a civilian federal agency, to Alamar Biosciences, Inc., a for-profit manufacturer of goods located in Fremont, California. The contract is for the provision of the NULISASEQ MOUSE PANEL, which involves proteomic mouse panel analysis to investigate potential biomarkers. The award does not have a set-aside designation, indicating open market competition. The contract period runs from...